Riccardo Autorino, MD, PhD, FEBU, presented “Cytoreductive Surgery in the Era of Targeted Therapy for Kidney Cancer: If Yes, When?” during the Jackson Hole Seminars on February 7, 2018 in Jackson Hole, Wyoming.

How to cite: Autorino, Riccardo. “Cytoreductive Surgery in the Era of Targeted Therapy for Kidney Cancer: If Yes, When?”   February 7, 2018. Accessed Jul 2024. https://grandroundsinurology.com/Cytoreductive-Surgery-in-the-Era-of-Targeted-Therapy/

Cytoreductive Surgery in the Era of Targeted Therapy for Kidney Cancer: If Yes, When?

Summary:

Riccardo Autorino MD, PhD, FEBU, discusses the decline in using cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) due to the shift toward targeted therapy in urological practice. He explains the rationale behind CN, its drawbacks, and individual scenarios in which it could provide a benefit, as opposed to targeted therapy and nephron-sparing surgery (NSS). Furthermore, he presents the current therapeutic algorithm for patient selection in these treatment options.

<script type="application/ld+json"><!-- [et_pb_line_break_holder] -->{<!-- [et_pb_line_break_holder] -->"@context": "http://schema.org",<!-- [et_pb_line_break_holder] -->"@type": "VideoObject",<!-- [et_pb_line_break_holder] -->"name": "Cytoreductive Surgery in the Era of Targeted Therapy for Kidney Cancer: If Yes, When?",<!-- [et_pb_line_break_holder] -->"description": "Riccardo Autorino MD, PhD, FEBU, discusses the decline in using cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) due to the shift toward targeted therapy in urological practice. He explains the rationale behind CN, its drawbacks, and individual scenarios in which it could provide a benefit, as opposed to targeted therapy and nephron-sparing surgery (NSS). Furthermore, he presents the current therapeutic algorithm for patient selection in these treatment options. ",<!-- [et_pb_line_break_holder] --><!-- [et_pb_line_break_holder] -->"thumbnailUrl": "https://grandroundsinurology.com/wp-content/uploads/2018/06/Cytoreductive-Surgery-in-the-Era-of-Targeted-Therapy-for-Kidney-Cancer-copy-2.png",<!-- [et_pb_line_break_holder] -->"uploadDate": "2018-06-12",<!-- [et_pb_line_break_holder] -->"duration": "19:45",<!-- [et_pb_line_break_holder] -->"publisher": {<!-- [et_pb_line_break_holder] --> "@type": "Organization",<!-- [et_pb_line_break_holder] --> "name": "Grand Rounds in Urology",<!-- [et_pb_line_break_holder] -->"logo": {<!-- [et_pb_line_break_holder] --> "@type": "ImageObject",<!-- [et_pb_line_break_holder] -->"url": "https://grandroundsinurology.com/wp-content/uploads/2016/11/GRU_WebMedium-e1480706258120.jpg"<!-- [et_pb_line_break_holder] -->}<!-- [et_pb_line_break_holder] -->},<!-- [et_pb_line_break_holder] -->"embedUrl": "https://player.vimeo.com/video/274482118" <!-- [et_pb_line_break_holder] -->}<!-- [et_pb_line_break_holder] --></script>

ABOUT THE AUTHOR

Riccardo Autorino, MD, PhD, FEBU

Dr. Autorino is an Associate Professor of Urology at Virginia Commonwealth University in Richmond. After graduating cum laude from Federico II Medical School in Napoli, Italy, Dr. Autorino completed his residency training in the same city, where he also obtained a PhD in Urological Sciences. In 2010, Dr. Autorino moved to the USA, where he first completed a two-year Research Fellowship in Urology, and then a two-year Clinical Fellowship in Advanced Laparoscopic & Robotic Surgery at the Glickman Urological Institute at the Cleveland Clinic in Cleveland, Ohio. In 2012, he was awarded with the Italian Matula Award by the Italian Society of Urology. In 2017, he was recipient of the Hans Marberger Award at the annual EAU meeting. Dr. Autorino serves as reviewer for numerous journals, and he serves as editorial board member of European Urology, World Journal of Urology, Archivos Espanoles de Urologia, and the International Brazilian Journal of Urology. He is the Associate Editor for the Laparoscopy and Robotics section of Minerva Urologica e Nefrologica. He has co-authored over 300 peer-reviewed publications and several book chapters. His main clinical interest is the minimally-invasive treatment of urologic cancers and benign urologic diseases by using robotic-assisted surgery.